162 related articles for article (PubMed ID: 35950406)
1. [Bipolar androgen therapy followed by immune checkpoint inhibitors in metastatic castration resistant prostate cancer: A report of 4 cases].
Liu SJ; Hou HM; Lv ZT; Ding X; Wang L; Zhang L; Liu M
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Aug; 54(4):766-769. PubMed ID: 35950406
[TBL] [Abstract][Full Text] [Related]
2. Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study.
Teply BA; Wang H; Luber B; Sullivan R; Rifkind I; Bruns A; Spitz A; DeCarli M; Sinibaldi V; Pratz CF; Lu C; Silberstein JL; Luo J; Schweizer MT; Drake CG; Carducci MA; Paller CJ; Antonarakis ES; Eisenberger MA; Denmeade SR
Lancet Oncol; 2018 Jan; 19(1):76-86. PubMed ID: 29248236
[TBL] [Abstract][Full Text] [Related]
3. A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts.
Markowski MC; Wang H; Sullivan R; Rifkind I; Sinibaldi V; Schweizer MT; Teply BA; Ngomba N; Fu W; Carducci MA; Paller CJ; Marshall CH; Eisenberger MA; Luo J; Antonarakis ES; Denmeade SR
Eur Urol; 2021 May; 79(5):692-699. PubMed ID: 32624280
[TBL] [Abstract][Full Text] [Related]
4. TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer.
Denmeade SR; Wang H; Agarwal N; Smith DC; Schweizer MT; Stein MN; Assikis V; Twardowski PW; Flaig TW; Szmulewitz RZ; Holzbeierlein JM; Hauke RJ; Sonpavde G; Garcia JA; Hussain A; Sartor O; Mao S; Cao H; Fu W; Wang T; Abdallah R; Lim SJ; Bolejack V; Paller CJ; Carducci MA; Markowski MC; Eisenberger MA; Antonarakis ES
J Clin Oncol; 2021 Apr; 39(12):1371-1382. PubMed ID: 33617303
[TBL] [Abstract][Full Text] [Related]
5. Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancer.
Markowski MC; Shenderov E; Eisenberger MA; Kachhap S; Pardoll DM; Denmeade SR; Antonarakis ES
Prostate; 2020 Apr; 80(5):407-411. PubMed ID: 31972048
[TBL] [Abstract][Full Text] [Related]
6. PSA provocation by bipolar androgen therapy may predict duration of response to first-line androgen deprivation: Updated results from the BATMAN study.
Denmeade S; Lim SJ; Isaaccson Velho P; Wang H
Prostate; 2022 Dec; 82(16):1529-1536. PubMed ID: 35938545
[TBL] [Abstract][Full Text] [Related]
7. Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trials.
Fallah J; Zhang L; Amatya A; Gong Y; King-Kallimanis B; Bhatnagar V; Weinstock C; Suzman DL; Agrawal S; Chang E; Anscher MS; Chi DC; Xu JX; Brewer JR; Brave MH; Hadadi M; Theoret MR; Kluetz PG; Goldberg KB; Ibrahim A; Tang S; Pazdur R; Beaver JA; Amiri-Kordestani L; Singh H
Lancet Oncol; 2021 Sep; 22(9):1230-1239. PubMed ID: 34310904
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of bipolar androgen therapy in mCRPC after progression on abiraterone or enzalutamide: A systematic review.
Xiong X; Qiu S; Yi X; Xu H; Lei H; Liao D; Bai S; Peng G; Wei Q; Ai J; Yang L
Urol Oncol; 2022 Jan; 40(1):4.e19-4.e28. PubMed ID: 34548234
[TBL] [Abstract][Full Text] [Related]
9. A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone.
Graff JN; Beer TM; Alumkal JJ; Slottke RE; Redmond WL; Thomas GV; Thompson RF; Wood MA; Koguchi Y; Chen Y; Latour E; Bergan RC; Drake CG; Moran AE
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32616555
[TBL] [Abstract][Full Text] [Related]
10. Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer.
Efstathiou E; Titus M; Wen S; Hoang A; Karlou M; Ashe R; Tu SM; Aparicio A; Troncoso P; Mohler J; Logothetis CJ
Eur Urol; 2015 Jan; 67(1):53-60. PubMed ID: 24882673
[TBL] [Abstract][Full Text] [Related]
11. Exposure-Response Assessment of Enzalutamide and Its Major Metabolites in a Real-World Cohort of Patients with Metastatic Castration-Resistant Prostate Cancer.
van Nuland M; Bergman AM; Rosing H; de Vries N; Huitema ADR; Beijnen JH
Pharmacotherapy; 2019 Dec; 39(12):1137-1145. PubMed ID: 31596947
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific Antigen Kinetics During Androgen-deprivation Therapy Predict Response to Enzalutamide in Metastatic Castration-resistant Prostate Cancer.
Nagata Y; Matsukawa T; Tomisaki I; Fujimoto N
Anticancer Res; 2023 Jan; 43(1):429-436. PubMed ID: 36585210
[TBL] [Abstract][Full Text] [Related]
13. Bipolar androgen therapy sensitizes castration-resistant prostate cancer to subsequent androgen receptor ablative therapy.
Sena LA; Wang H; Lim ScM SJ; Rifkind I; Ngomba N; Isaacs JT; Luo J; Pratz C; Sinibaldi V; Carducci MA; Paller CJ; Eisenberger MA; Markowski MC; Antonarakis ES; Denmeade SR
Eur J Cancer; 2021 Feb; 144():302-309. PubMed ID: 33383350
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Novel Hormone Agents in the Treatment of Metastatic Castration-resistant Prostate Cancer: A Real-world Retrospective Study.
Li JR; Wang SS; Chen CS; Yang CK; Lu K; Cheng CL; Hung SC; Chen SY; Hsu CY; Chiu KY
Anticancer Res; 2022 Oct; 42(10):4857-4866. PubMed ID: 36191989
[TBL] [Abstract][Full Text] [Related]
15. Clinical and molecular determinants of PSA response to bipolar androgen therapy in prostate cancer.
Caputo SA; Hawkins M; Jaeger EB; Fleming W; Casado C; Manogue C; Huang M; Lieberman A; Light M; Sussman IP; Miller P; Barata PC; Lewis BE; Layton JL; Ledet EM; Antonarakis ES; Sartor O
Prostate; 2023 Jun; 83(9):879-885. PubMed ID: 36959766
[TBL] [Abstract][Full Text] [Related]
16. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
[TBL] [Abstract][Full Text] [Related]
17. Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study.
Schweizer MT; Antonarakis ES; Wang H; Ajiboye AS; Spitz A; Cao H; Luo J; Haffner MC; Yegnasubramanian S; Carducci MA; Eisenberger MA; Isaacs JT; Denmeade SR
Sci Transl Med; 2015 Jan; 7(269):269ra2. PubMed ID: 25568070
[TBL] [Abstract][Full Text] [Related]
18. Prostate-specific Antigen Progression in Enzalutamide-treated Men with Nonmetastatic Castration-resistant Prostate Cancer: Any Rise in Prostate-specific Antigen May Require Closer Monitoring.
Saad F; Sternberg CN; Efstathiou E; Fizazi K; Modelska K; Lin X; Sugg J; Steinberg J; Noerby B; Shore ND; Hussain M
Eur Urol; 2020 Dec; 78(6):847-853. PubMed ID: 33010985
[TBL] [Abstract][Full Text] [Related]
19. Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer.
Madan RA; Karzai F; Donahue RN; Al-Harthy M; Bilusic M; Rosner II; Singh H; Arlen PM; Theoret MR; Marté JL; Cordes L; Couvillon A; Hankin A; Williams M; Owens H; Lochrin SE; Chau CH; Steinberg S; Figg WD; Dahut W; Schlom J; Gulley JL
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33664086
[TBL] [Abstract][Full Text] [Related]
20. Enzalutamide in patients with non-metastatic castration-resistant prostate cancer after combined androgen blockade for recurrence following radical treatment in Japan (Japanese research for patients with non-metastatic castration-resistant prostate cancer-enzalutamide: JCASTRE-zero)-a prospective single-arm interventional study.
Sugimoto M; Kato T; Tohi Y; Shimizu Y; Matsumoto R; Inoue T; Takezawa Y; Masui K; Sasaki H; Hirama H; Saito S; Egawa S; Kamoto T; Teramukai S; Kojima S; Kikuchi T; Kakehi Y
BMC Urol; 2022 Sep; 22(1):151. PubMed ID: 36104667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
